PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.
MHE December 2024
Roche’s Evrysdi is the market leader among the drugs for spinal muscular atrophy. Biogen’s Spinraza has struggled, but company officials express confidence about future sales.
On financial toxicity, and when, how and by whom it should be discussed.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
California PBM Law is a Starting Point for Real Transparency
2
WeightWatchers Launches Employer Program for GLP-1 Drugs
3
Professional Pickleball Players Most Likely to Sustain Eye Injury, Least Likely to Wear Eye Protection, Survey Shows | 2025 AAO
4
Medicare Provides Coverage, But Care Depends on Location
5
